Loading...
Market
What will be Pfizer's top revenue-generating product in Q4 2024?
2
Resolution / Starting Odds
Paxlovid • 25%
Comirnaty • 25%
Prevnar • 25%
Other • 25%
Pfizer's Q4 2024 financial report
Story
Pfizer Beats Q3 Estimates, Raises Guidance by $1.5B as COVID-19 Treatment Sales Surge
Oct 30, 2024, 10:58 AM
Pfizer Inc. reported strong third-quarter 2024 financial results, surpassing Wall Street estimates and raising its full-year guidance by $1.5 billion. The pharmaceutical giant's revenue climbed 32% year-over-year to $17.7 billion, exceeding analysts' expectations of $15.2 billion. Adjusted earnings per share reached $1.06, beating estimates by $0.44. The company's performance was bolstered by better-than-expected sales of its COVID-19 treatment, Paxlovid. As a result, Pfizer raised its full-year 2024 adjusted EPS guidance to a range of $2.75 to $2.95, up from the previous forecast of $2.45 to $2.65, and increased its revenue guidance by $1.5 billion to $61.0 billion to $64.0 billion. The strong quarterly results and optimistic outlook led to a 2% rise in Pfizer's stock in pre-market trading.
View original story
Similar markets
Covid vaccine • 25%
Paxlovid • 25%
Other Pharmaceutical Product • 25%
Other Vaccine • 25%
Cancer drugs • 25%
COVID-19 treatment • 25%
Vaccines • 25%
Other pharmaceuticals • 25%
Migraine medication • 25%
COVID-19 medication • 25%
Flu medication • 25%
Respiratory illness medication • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Less than $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
More than $12 billion • 25%
Less than $85 billion • 25%
$85 billion to $90 billion • 25%
$90 billion to $95 billion • 25%
More than $95 billion • 25%
COVID-19 Vaccine • 25%
RSV Vaccine • 25%
Other Products • 25%
No clear top-seller • 25%
Less than $60 billion • 25%
$60 billion to $65 billion • 25%
$65 billion to $70 billion • 25%
More than $70 billion • 25%
Skyrizi • 25%
Rinvoq • 25%
Humira • 25%
Other • 25%
Moderna • 25%
Pfizer/BioNTech • 25%
Novavax • 25%
Other • 25%